PT699077E - Complexo imunogenico de hiv - Google Patents
Complexo imunogenico de hivInfo
- Publication number
- PT699077E PT699077E PT94917313T PT94917313T PT699077E PT 699077 E PT699077 E PT 699077E PT 94917313 T PT94917313 T PT 94917313T PT 94917313 T PT94917313 T PT 94917313T PT 699077 E PT699077 E PT 699077E
- Authority
- PT
- Portugal
- Prior art keywords
- hiv
- immunogenic complex
- immunogenic
- concanvalin
- succinyl
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6092693A | 1993-05-07 | 1993-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT699077E true PT699077E (pt) | 2002-04-29 |
Family
ID=22032603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT94917313T PT699077E (pt) | 1993-05-07 | 1994-05-06 | Complexo imunogenico de hiv |
Country Status (10)
Country | Link |
---|---|
US (6) | US5843454A (pt) |
EP (1) | EP0699077B1 (pt) |
JP (1) | JPH08510246A (pt) |
AT (1) | ATE207760T1 (pt) |
AU (1) | AU680916B2 (pt) |
DE (1) | DE69428896T2 (pt) |
DK (1) | DK0699077T3 (pt) |
ES (1) | ES2166779T3 (pt) |
PT (1) | PT699077E (pt) |
WO (1) | WO1994026305A1 (pt) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6165710A (en) * | 1989-10-23 | 2000-12-26 | Robinson; James E. | Method for immobilizing viral glycoproteins for use in solid-phase immunoassays |
US20040076636A1 (en) * | 1993-05-07 | 2004-04-22 | Ranajit Pal | HIV immunogenic complexes |
US8038994B2 (en) * | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
US20060159688A1 (en) * | 1996-05-15 | 2006-07-20 | Ragupathy Madiyalakan | Method for diagnosing efficacy of xenotypic antibody therapy |
ES2193240T3 (es) * | 1996-05-15 | 2003-11-01 | Altarex Inc | Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune. |
AU3960797A (en) * | 1996-06-28 | 1998-01-21 | Dana-Farber Cancer Institute | Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection |
US7063850B1 (en) * | 1998-12-22 | 2006-06-20 | University Of Tennessee Research Foundation | Protective antigen of group A Streptococci |
FR2789590B1 (fr) * | 1999-02-15 | 2003-01-17 | Inst Rech Developpement Ird | Compositions immunogenes utilisables comme vaccins |
US7115262B1 (en) | 1999-03-16 | 2006-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric protein for prevention and treatment of HIV infection |
US7311920B1 (en) | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
DK1137786T3 (da) * | 1999-10-08 | 2007-08-06 | Univ Maryland Biotech Inst | Viruscoatprotein/receptorkimærer og fremgangsmåder til brug heraf |
US6908612B2 (en) * | 1999-10-08 | 2005-06-21 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
FR2799974B1 (fr) * | 1999-10-25 | 2001-11-30 | Aventis Pasteur | Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih |
US6503736B1 (en) * | 1999-11-12 | 2003-01-07 | BIOMéRIEUX, INC. | Antibodies to crosslinkers and methods for using the same |
BR0114094A (pt) | 2000-09-22 | 2003-07-22 | Univ Duke | Imunógeno |
US7033593B2 (en) * | 2000-09-22 | 2006-04-25 | Duke University | Immunogen comprising an HIV envelope protein, a ligand and H2 peptide |
AU2002243392A1 (en) * | 2000-12-27 | 2002-07-30 | Dana-Farber Cancer Institute, Inc. | Immunogenic proteoliposomes, and uses thereof |
AU2002335932B2 (en) * | 2001-03-21 | 2007-11-01 | Altarex Medical Corp. | Therapeutic compositions that alter the immune response |
AU2002337885B1 (en) * | 2001-10-16 | 2003-04-28 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive neutralizing antibodies against human ummunodeficiency virus selected by Env-CD4-co-receptor complexes |
CA2481796A1 (en) * | 2002-04-11 | 2003-10-23 | Altarex Medical Corporation | Binding agents and their use in targeting tumor cells |
WO2003095492A1 (en) * | 2002-05-06 | 2003-11-20 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
CA2484930A1 (en) * | 2002-05-06 | 2003-11-13 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries |
US7811580B2 (en) | 2002-05-07 | 2010-10-12 | Novartis Vaccines & Diagnostics, Inc. | Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes |
CA2472438A1 (en) * | 2002-06-28 | 2004-01-08 | Fuso Pharmaceutical Industries, Ltd. | Mannose binding protein for use in anti-hiv treatment |
JP2005535636A (ja) | 2002-06-28 | 2005-11-24 | アメリカ合衆国 | インターフェロンβおよびIL−2Rアンタゴニストを用いて自己免疫疾患を治療する方法 |
KR20050036960A (ko) * | 2002-07-23 | 2005-04-20 | 듀크 유니버시티 | IgG Fc/HIV-gp120/C3d 융합 단백질 |
JP4038679B2 (ja) * | 2003-05-13 | 2008-01-30 | 住友電気工業株式会社 | 半導体レーザーバーの固定用治具 |
WO2005111621A2 (en) * | 2004-04-16 | 2005-11-24 | Uab Research Foundation | Molecular scaffolds for hiv-1 epitopes |
US8206720B2 (en) | 2004-06-08 | 2012-06-26 | Novartis Vaccines & Diagnostics, Inc | Fusion proteins comprising CD4 minimal modules and invasin polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutraliziation epitopes |
WO2006026097A2 (en) * | 2004-08-25 | 2006-03-09 | Vijay Ramakrishnan | Pegylation of antibodies against hiv |
US20080038280A1 (en) * | 2004-10-14 | 2008-02-14 | Government Of The United States Of America | A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines |
AU2005302416A1 (en) * | 2004-10-29 | 2006-05-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies |
ATE471947T1 (de) * | 2005-02-03 | 2010-07-15 | Novartis Vaccines & Diagnostic | Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür |
US8647818B2 (en) * | 2005-02-18 | 2014-02-11 | UAB Research Foundation, University of Alabama—Birmingham | Molecular scaffolds for HIV-1 immunogens |
CN101313216A (zh) * | 2005-09-22 | 2008-11-26 | 普洛茨股份有限公司 | 酵母突变体中产生的糖基化多肽及其使用方法 |
US20100104580A1 (en) * | 2008-09-03 | 2010-04-29 | Philadelphia Health & Education Corporation D/B/A | Altered Immunogenic Landscape in HIV-1 Envelope Proteins |
US20110212119A1 (en) * | 2008-10-31 | 2011-09-01 | Proteonova, Inc. | Methods for making hiv vaccines and related compositions |
US8340810B2 (en) * | 2008-10-31 | 2012-12-25 | Spectra Logic Corp. | Robotic storage library with queued move instructions and method of queuing such instructions |
US9228171B2 (en) | 2010-02-05 | 2016-01-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulatory B cells (tBREGS) and their use |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
CN103797029B (zh) * | 2011-05-17 | 2016-08-17 | 洛克菲勒大学 | 人类免疫缺陷病毒中和抗体及其使用方法 |
HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
US20150175678A1 (en) * | 2012-06-15 | 2015-06-25 | Beth Israel Deaconess Medical Center, Inc. | IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
CA2930587A1 (en) | 2013-11-25 | 2015-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
US20160362478A1 (en) * | 2014-02-10 | 2016-12-15 | Navid Madani | Cd4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies |
WO2016025681A1 (en) | 2014-08-13 | 2016-02-18 | The Trustees Of The University Of Pennsylvania | Inhibitors of hiv-1 entry and methods of use thereof |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2011299A1 (en) * | 1989-03-03 | 1990-09-03 | Franklin Volvovitz | Aids therapy |
EP0550516A1 (en) * | 1990-09-28 | 1993-07-14 | Hospital For Joint Diseases | Method for inhibiting the infectivity of human immunodeficiency virus |
-
1994
- 1994-05-06 AT AT94917313T patent/ATE207760T1/de active
- 1994-05-06 PT PT94917313T patent/PT699077E/pt unknown
- 1994-05-06 AU AU69073/94A patent/AU680916B2/en not_active Ceased
- 1994-05-06 JP JP6525565A patent/JPH08510246A/ja active Pending
- 1994-05-06 WO PCT/US1994/005020 patent/WO1994026305A1/en active IP Right Grant
- 1994-05-06 ES ES94917313T patent/ES2166779T3/es not_active Expired - Lifetime
- 1994-05-06 EP EP94917313A patent/EP0699077B1/en not_active Expired - Lifetime
- 1994-05-06 DK DK94917313T patent/DK0699077T3/da active
- 1994-05-06 DE DE69428896T patent/DE69428896T2/de not_active Expired - Lifetime
- 1994-05-06 US US08/464,680 patent/US5843454A/en not_active Expired - Lifetime
-
1995
- 1995-05-08 US US08/437,250 patent/US5518723A/en not_active Expired - Lifetime
-
1998
- 1998-05-11 US US09/075,544 patent/US6030772A/en not_active Expired - Lifetime
-
2000
- 2000-01-07 US US09/479,675 patent/US6328973B1/en not_active Expired - Fee Related
-
2001
- 2001-07-17 US US09/905,962 patent/US20030039663A1/en not_active Abandoned
- 2001-07-17 US US09/905,963 patent/US6465172B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1994026305A1 (en) | 1994-11-24 |
JPH08510246A (ja) | 1996-10-29 |
US6328973B1 (en) | 2001-12-11 |
EP0699077A1 (en) | 1996-03-06 |
ES2166779T3 (es) | 2002-05-01 |
DE69428896T2 (de) | 2002-06-20 |
EP0699077B1 (en) | 2001-10-31 |
US20030039663A1 (en) | 2003-02-27 |
US5843454A (en) | 1998-12-01 |
AU680916B2 (en) | 1997-08-14 |
DE69428896D1 (de) | 2001-12-06 |
DK0699077T3 (da) | 2002-01-21 |
US6465172B1 (en) | 2002-10-15 |
ATE207760T1 (de) | 2001-11-15 |
US6030772A (en) | 2000-02-29 |
AU6907394A (en) | 1994-12-12 |
US5518723A (en) | 1996-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT699077E (pt) | Complexo imunogenico de hiv | |
MY108864A (en) | Peptide-carbohydrate conjugates generating t-cell immunity | |
CA2082948A1 (en) | Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding | |
SG77551A1 (en) | Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing | |
ATE122237T1 (de) | Hiv-1 neutralisierende monoklonale antikörper. | |
AU606951B2 (en) | Synthetic peptide antigen for the detection of hiv-2 infection | |
AU4985496A (en) | Administration of a cyclosporine-specific monoclonal antibody that cross-reacts with hiv-1 p24 gag to treat hiv infection | |
AU5510794A (en) | Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type I (HIV-1) gp120 and methods of use | |
AU563356B2 (en) | Conjugate of enzyme and antibody | |
AU8083594A (en) | Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus | |
DE68906366D1 (en) | Cd4-polypeptidderivate. | |
DE69029937D1 (de) | FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER | |
ES2182833T3 (es) | Agentes antitromboticos multimeros polivalentes. | |
CA2091263A1 (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
DE69332911D1 (de) | Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus | |
GR1002294B (el) | Συνδυασμενο εμβολιο για streptococcus ομαδας β. | |
DE69435142D1 (de) | Methoden zur Inhibition von HIV-assoziierten Krankheiten mittels monoklonaler Antikörper gegen sich selbstgerichtete zytotoxische T-Zellen | |
CA2160922A1 (en) | Hiv immunogenic complexes | |
AU4959193A (en) | High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus | |
AU5695294A (en) | Monoclonal antibodies against a carbohydrate-dependent epitope related to the V2 region of HIV-1 GP120 | |
EP0345559A3 (en) | Hiv-2 variants | |
AU627540B2 (en) | Drug for the treatment or prevention by passive immunization, of the hiv-infection and process for preparation thereof | |
DE68926454T2 (de) | Gegen hiv 1 gp48 spezifische antikörper | |
BG98538A (en) | Means for anti-hiv therapy | |
RU95122192A (ru) | Сем-к - штамм перевиваемых клеток человека, устойчивый к вич-инфекции |